BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-817@pharmaconomics
DTSTAMP:20260707T033835Z
DTSTART;VALUE=DATE:20260401
DTEND;VALUE=DATE:20260402
SUMMARY:PTGX Phase 2 — ICOTYDE
DESCRIPTION:Phase 2 trial results for ICOTYDE in plaque psoriasis are due Apr 1\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1377121/000110465926019658/tm267184d1_ex99-1.htm\n\nTrack it: https://pharmaconomics.com/e/817
URL:https://pharmaconomics.com/e/817
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:PTGX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR